Aim/Objectives/Background: Angiotensin-converting enzyme inhibitors (ACEIs) increase potent proinflammatory and pain mediators in local tissues. Consistent with these observations, animal and human studies demonstrate that ACEIs have hyperalgesic and proinflammatory properties. However, there is no information in literature whether or not the use of ACEIs is associated with increased postoperative pain. Specifically, we tested the primary hypothesis that use of ACEIs is independently associated with increased opioid requirements and pain scores during the initial 72 hours after surgery.
S
urgery causes pain by directly activating nociceptors, provoking inflammation, and injuring nerves. The inflammatory response to surgical incisions-including release of inflammatory mediators such as bradykinin, substance P, and histamine-sensitizes local afferent nociceptors which is known as peripheral sensitization. 1, 2 Peripheral pain also enhances excitability of neurons in the spinal cord and brain, which is known as central sensitization. 3, 4 Inflammation thus plays a crucial role in maintaining postoperative pain until healing, 5, 6 and even longer in patients who develop persistent incisional pain. 5, 7 Angiotensin-converting enzyme inhibitors (ACEIs) are commonly prescribed to treat hypertension and heart failure. It is estimated that as many as 149 million prescriptions for ACE Inhibitors are filled in the United States each year, making ACE inhibitors one of the most popular drug groups. 8 A consequence of frequent use of ACE inhibitors is that an increasing fraction of surgical patients take these drugs.
The rennin-angiotensin system modulates nociception both centrally and peripherally. ACEIs prevent conversion of angiotensin I to II, thus decreasing angiotensin II concentrations. 9 Angiotensin II has central analgesic effects. 10 Furthermore, angiotensin-converting enzyme is identical to kininase II, an enzyme involved in the degradation of bradykinin and substance P. Thus, ACEIs increase concentrations of potent proinflammatory and pain mediators such as bradykinin and substance P in local tissues. 9, 11, 12 Consistent with these observations, animal models demonstrate that ACEIs are both hyperalgesic and proinflammatory. 13, 14 Furthermore, ACEIs enhance pain perception and are associated with complex regional pain syndrome in humans. 13, 14, 15 Surgical incision releases inflammatory mediators, reducing the pain threshold at the site of injury and in surrounding uninjured tissue. The combination of ACEIs and surgical incision may thus be especially deleterious. However, determined by a text search of the patients' medication history. The medication history data are not always accurate or up-to-date; thus, ACE inhibitor use was later validated by a clinical review of electronic medical records. It is our routine, although, to instruct patients who normally take ACEIs to continue until the day before surgery, but not to take them the morning of surgery. Patients with unavailable medication history and emergent patients were excluded from the study population, as were patients receiving regional anesthesia or epidural analgesia. A propensity-matching procedure was used to pair ACE inhibitor users to presumed nonusers. Propensity scores were estimated using multivariable logistic regression with backward stepwise variable selection. All the variables listed in Table 2 were considered for the propensity score model. We used an exact matching algorithm to perform the matching, restricting successful matches to those with common type of surgery and common propensity scores (to within 2 decimal places). Observations were randomly ordered before the matching to minimize any time biases.
After successfully matching 1038/1189 patients with ACE inhibitors listed in their medication history to controls with no such records, we proceeded to perform a manual review of the matched patients' electronic medical records to confirm ACE inhibitor use and anesthetic modality. Also, while postoperative pain scores are generally available in our registry, postoperative opioid consumption data are not available in adequate detail. These data were therefore recorded during the manual review. Pairs for which at least one of the patients had an incorrect classification of ACE inhibitor use or received regional anesthesia were removed.
A prior power analysis was performed to estimate the number of conforming pairs we needed to obtain from the manual electronic medical record review process. Assuming clinically relevant effects of at least ± 0.5 units for the difference in mean verbal rating scale pain score and at least ± 30% for the percent difference in mean total intravenous (IV) morphine equivalent dose, a subsample of 101 pairs was adequate to supply at least 90% power. This power calculation was performed a priori and incorporated Bonferroniadjusted nominal significance levels of 0.025, a SD of mean verbal rating scale pain score of 1.0 and a coefficient of variation for total IV morphine equivalent dose equal to 0.5, or 50% of the mean. Thus, our manual review proceeded until we had at least 101 pairs that conformed to the study inclusion/exclusion criteria. At the end of our search, however, we actually had 106 conforming pairs (Fig. 1) .
For the analysis among the final subsample of 106 pairs, we first assessed balance between the ACE inhibitor group and the non-ACE inhibitor group. This was done graphically using absolute standardized differences (ASDs). The ASD, equal to the absolute value of the difference in means, mean rankings, or proportions divided by the pooled SD, is a measure of statistical distance between 2 groups on a covariable; values >0.2 are considered to be indicative of at least small imbalance between the 2 groups 16 that might thus potentially confound the relationship of interest. We thus adjusted for any potential confounding variables with an ASD > 0.2 in all subsequent analyses.
Two simultaneous hypotheses were evaluated. The first was that matched ACE inhibitor users and nonusers differed on mean 72-hour postoperative pain scores summarized using a time-weighted average (TWA) algorithm. The second was that matched ACE inhibitor users and nonusers differed on mean 72-hour postoperative opioid requirements as characterized by milligrams IV morphine equivalent dose (Table 1) .
To accomplish this testing, outcome-specific multivariable linear regression models were developed. These regression models included all imbalanced potential confounding variables as described by the ASD criterion above. A logarithmic transformation of IV morphine equivalent dose was performed before analysis to meet modeling assumptions. To avoid taking the logarithm of 0 which is undefined, we added 0.1 mg morphine equivalent to those receiving no opioids. Standard t tests for linear regression model coefficients were used for this testing.
An outcome-specific significance criterion of P < 0.025 was used for each of the tests to ensure an overall type I (false positive) error rate of 5% for the entire study (Bonferroni correction). Corresponding estimates and Bonferroni-adjusted 95% confidence intervals for the effect of ACE inhibitors on each outcome were also estimated. R Statistical software version 2.11.1 for Windows (The R Foundation for Statistical Computing, Vienna, Austria) was used for all statistical analysis.
RESULTS
There were 9555 patients who met our inclusion/ exclusion criteria, of whom 1241 (13.0%) were taking ACE inhibitors before their surgery (Fig. 1) . Patients taking ACE FIGURE 2. Balance of patient characteristics before and after exact matching on propensity score (rounded to the nearest percentage) and type of surgery, as well as among the 100 matched pairs included in the final analysis, as characterized by absolute standardized differences (ASDs). The ASD, equal to the difference in means, mean rankings, or proportions divided by the pooled SD, is a measure of statistical distance between 2 groups on a characteristic; values >0.2 are indicative of imbalance between the 2 groups (and thus potential confounding on the relationship of interest). Age, American Society of Anesthesiologists Physical Status, and supraventricular arrhythmia displayed marginal imbalance among the 212 patients included in the final analysis and were hence, adjusted for within the multivariable linear regression models. ASA indicates American Society of Anesthesiologists; BMI, body mass index; Ca, calcium; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; S/P, status/post.
inhibitors were more likely to be hypertensive, to be using statins, b-blockers, and calcium channel blockers, more likely to have coronary artery disease, to have had congestive heart failure, myocardial infarction, and/or percutaneous coronary intervention, more likely to be older, and have a higher American Society of Anesthesiologists (ASA) Physical Status ( Table 2) .
The stepwise multivariable logistic regression model developed for the estimation of propensity scores identified the following factors as predictive of ACE inhibitors being listed in the medication history: sex, year of surgery, ASA Physical Status, systolic blood pressure, hypertension, history of congestive heart failure, previous coronary artery bypass grafting, steroid use, b-blocker use, angiotensin II receptor blocker use, calcium channel blocker use, and statin use. Estimation of the propensity scores was not possible for 524 patients (5.5%) because of missing data on these factors.
The exact matching procedure, based on type of surgery and propensity score (rounded to the nearest percentage), identified 1038 matched pairs. ASD scores for the factors identified as displaying imbalance (as defined by ASD >0.2) between ACE inhibitor users and nonusers before matching were much smaller after matching (Fig. 2) . Postoperative opioid data were ascertained from electronic medical records for a total of 106 matched pairs (see above); this required the review of 199 matched pairs as 93 pairs contained at least 1 patient who did not meet the inclusion/exclusion criteria or whose medication history did not accurately reflect their actual ACE inhibitor usage. ACEI drug distribution in propensity-matched patients is given in Table 3 . Thus, our final analyzed subsample was of size N = 212. A graphical summary of pain scores and opioid consumption is given in Figure 3 .
Within this final subsample, covariables were generally well-balanced, except for age (ASD = 0.29), ASA physical status (ASD = 0.36), and supraventricular arrhythmia (ASD = 0.23, Fig. 2) . We adjusted for these 3 factors within our linear regression models assessing the relationship between ACE inhibitor use and, respectively, mean TWA pain score and total postoperative opioid consumption; ASA physical statuses III and IV were combined during modeling because of small cell sizes.
We found no differences in pain scores or opioid requirements after adjusting for these factors. The adjusted difference (Bonferroni-adjusted 95% confidence interval) in mean 72-hour postoperative TWA pain score (ACE inhibitor users, relative to nonusers) was estimated at + 0.17 [À0.40, + 0.74] units on the verbal response scale, which was not statistically significant (P = 0.50, linear model t test).
For opioid use, we estimated the percent difference in mean 72-hour total postoperative IV morphine equivalent dose at À 8.1% [À46%, + 56%], which was also not statistically significant (P = 0.72). Adjusted mean TWA pain score was 3. 
DISCUSSION
ACEIs potentially augment pain perception by either decreasing plasma angiotensin II and/or increasing tissue bradykinin and substance P levels, effects that are manifested clinically as regional pain in patients who take ACEIs. 17, 18 Bradykinin is an important mediator of inflammation and pain, acting on nerve terminals to contribute to peripheral sensitization. Bradykinin also produces central sensitization which may augment acute pain. 19 This theory is supported by the observation that pain intensity in human volunteers after muscle contraction correlates with the concentration of tissue bradykinin; and that administration of ACEIs further augments bradykinin concentrations and pain intensity. 20 Angiotensin II has central and peripheral antinociceptive effects with role in regulation of pain and inflammation. The effects of angiotensin II are through presynaptic AT1 inhibition of GABAergic inputs in midbrain periaqueductal gray. 21, 22 The antinociceptive role has been demonstrated in the incisional pain model 23 and trigeminal neuralgia. 22 Furthermore, ACEIs prevent migraines by preventing formation of angiotensin II, independent of their effect on blood pressure. 24, 25 There were thus well-established reasons to expect patients given ACEIs to experience more postoperative pain. Surprisingly, although, we did not find a significant difference in postoperative pain scores or opioid requirements in patients taking ACEIs.
Our study appears to be the first specifically evaluating the relationship between ACEI use and postoperative pain-and contrast with nonoperative pain studies. For example, Schrader et al 26 demonstrated that ACEIs cause dose-dependent hyperalgesia after thermal injury. Furthermore, a single dose of ACEI in normotensive volunteers decreases the pain perception threshold and increases maximum tolerated pain, indicated that ACEIs cause algesia. 27 And finally, ACEI use is associated with complex regional pain syndrome, possibly by an ACEI-induced increase in substance P and bradykinin. 14 The difference of our results from previous nonsurgical studies suggests the possibility that ACEI effect is relatively small and overwhelmed by intense surgical pain.
Interactions between pain sensitivity and the cardiovascular system are well established. Hypertension in animal and human models is associated with reduced sensitivity to pain. 28 And as might thus be expected, antihypertensive medications reverse reduced pain perception. [29] [30] [31] Consistent with this, treatment with ACEIs (enalapril) in hypertensive humans was found to decrease blood pressure but increase sensitivity to pain. [31] [32] [33] Increase in pain sensitivity with different ACEIs seems to vary; enalapril, captopril, ramipril, and lisinopril seems to be the most effective. 32 These were the ACEIs that most of our patients took.
Any retrospective analysis, including ours, potentially suffers from selection bias and confounding that are normally largely prevented by randomization. However, we used propensity matching to assemble groups that were comparable on available baseline and surgical factors, even matching exactly on the type of surgery. We also excluded patients with chronic pain whose pain scores and opioid requirements might have been difficult to interpret. It nonetheless remains possible that the treatment groups differed substantially on important factors that are not included in our registry or otherwise available to us. For example, we do not know how well patients complied with their ACEI prescriptions, nor what doses they took.
Perhaps the most serious limitation of our analysis is that while we routinely ask patients not to take ACEIs the morning of surgery, we do not know whether they actually did. Most of the putative mechanisms by which ACEIs are likely to increase surgical pain would seem insensitive to short interruptions of therapy, but the time course of any hyperalgesic efficacy remains unknown. To the extent that continuous ACEI treatment is necessary for hyperalgesia, our patients may not have been a good test. We note, although, that ACEIs usually are held the morning of surgery because of hypotensive concerns. The same concern is not valid for postoperative day 2 and 3, when patients reinitiate their ACEIs. Our results are thus generally applicable.
This is the first clinical study evaluating the role of ACEIs on postoperative pain and opioid consumption. After controlling for all available factors, we found no significant evidence that postoperative pain-as defined by either pain scores or opioid requirements-differed between patients taking ACE inhibitors and patients not taking ACE inhibitors. Perioperative ACEI management should thus be guided by hemodynamic considerations rather than the drugs' putative hyperalgesic effects.
